DENGUE

Endemic in over Endemic in

100 Countries[3] over 100
Countries[3]

ZIKA

86 Countries

now show evidence
OF ZIKA VIRUS INFECTION[2] now show
evidence OF
ZIKA VIRUS INFECTION[2]

NOROVIRUS

estimated $60.3 BILLION

estimated
$60.3 BILLION
ANNUAL ECONOMIC
IMPACT WORLDWIDE[2]

ANNUAL ECONOMIC
IMPACT WORLDWIDE[2]

Scroll

THE NUMBERS ARE CHANGING

Take a closer look at worldwide infectious disease facts and statistics. Take a closer look at worldwide infectious
disease facts and statistics.

Map shows areas at risk for dengue transmission.
Map shows areas that have or have had Zika transmission.
Map shows areas with the risk of norovirus transmission.

Dengue facts

About 50% of the world's population lives under the threat of dengue, which is responsible for approximately 390 million infections globally per year.^[3]
Dengue facts

Before 1970, only nine countries had experienced severe dengue epidemics. The disease is now endemic in more than 100 countries.^[3]
Zika facts

As of July 2018, a total of 86 countries and territories have reported evidence of mosquito-transmitted Zika infection.^[1]
Zika facts

As of March 2017, a decline in cases of Zika infection has been reported in some countries, or in some parts of countries; WHO advises that vigilance needs to remain high.^[1]
Norovirus facts

Norovirus is the most common viral cause of acute gastroenteritis worldwide, responsible for greater than 90% of epidemic non-bacterial outbreaks of gastroenteritis.^[2]
Norovirus facts

Norovirus is estimated to cause more than 699 million illness cases each year.^[2]
Interested in
Learning More?

For updated disease information and statistics, please visit the following websites:

World Health Organization

Centers for Disease Control and Prevention

Back to disease facts and statistics

vaccines change numbers

If all children were

immunized

with existing

vaccines, by 2020

we would

save nearly

25,000,000

lives

If all children were immunized with

existing vaccines,

by 2020 we would

save nearly

25,000,000 lives[6]

Estimated

2-3 MILLION

deaths averted each year with

immunization

from diphtheria, tetanus,

pertussis (whooping cough), and measles

Estimated 2-3 MILLION

deaths averted each year with

immunization

from diphtheria, tetanus, pertussis (whooping cough), and measles ^[7]

vaccines change lives

infectious diseases
that need our attention

infectious diseases that
need our attention

Learn about some of the diseases we are focusing on. Learn about some of the diseases
we are focusing on.

About the disease

Dengue fever is the world’s fastest spreading mosquito-borne viral disease with about 50% of the world's population at risk for contracting the disease. Dengue fever affects children and adults alike with flu-like symptoms and potentially deadly complications.^[3]

About the disease:

Zika is a mosquito-borne virus that can be passed from a pregnant woman to her fetus. Though many infected people will not develop any symptoms at all, approximately 10% of congenital infections are associated with Zika virus-associated birth defects. WHO says that 31 countries have currently reported microcephaly and other central nervous system defects potentially associated with Zika virus.^[1]

About the disease:

Norovirus is the most common cause of acute gastroenteritis worldwide. It is highly infectious and easily spreads, mainly through person-to-person contact. All age groups are impacted with the greatest burden on young children, older adults, and other vulnerable populations.^[8]

About the disease

Dengue fever is the world’s fastest spreading mosquito-borne viral disease with about 50% of the world's population at risk for contracting the disease. Dengue fever affects children and adults alike with flu-like symptoms and potentially deadly complications.^[3]

About the disease:

Zika is a mosquito-borne virus that can be passed from a pregnant woman to her fetus. Though many infected people will not develop any symptoms at all, approximately 10% of congenital infections are associated with Zika virus-associated birth defects. WHO says that 31 countries have currently reported microcephaly and other central nervous system defects potentially associated with Zika virus.^[1]

About the disease:

Norovirus is the most common cause of acute gastroenteritis worldwide. It is highly infectious and easily spreads, mainly through person-to-person contact. All age groups are impacted with the greatest burden on young children, older adults, and other vulnerable populations.^[8]

WHO WE ARE

OUR VISION

To protect the health of people everywhere through vaccines that address the most important infectious diseases.

OUR MISSION

To develop and deliver innovative vaccines that tackle the toughest problems in public health and improve the lives of people around the world.

OUR VALUES

In our day-to-day work, we focus on the following values while upholding the highest ethical standards:

Fairness
Honesty

Integrity
Perseverence

OUR PRODUCTS

OUR PRODUCTS MARKETED IN JAPAN

BLB-750 (H5N1 Flu)
Measles Rubella
Mumps
Diphtheria Tetanus Toxoid
Seasonal Flu (Denka & Kaketsuken)
Varicella (Biken)
Japanese Encephalitis (Biken)

OUR VISION

To protect the health of people everywhere through vaccines that address the most important infectious diseases.

OUR MISSION

To develop and deliver innovative vaccines that tackle the toughest problems in public health and improve the lives of people around the world.

OUR VALUES

In our day-to-day work, we focus on the following values while upholding the highest ethical standards:

Fairness
Honesty

Integrity
Perseverence

OUR PRODUCTS

OUR PRODUCTS MARKETED IN JAPAN

BLB-750 (H5N1 Flu)
Measles Rubella
Mumps
Diphtheria Tetanus Toxoid
Seasonal Flu (Denka & Kaketsuken)
Varicella (Biken)
Japanese Encephalitis (Biken)

WE'RE COMMITTED
TO A HEALTHIER FUTURE

Here's what we are working on: Here's what we are working on:

View Clinical Trials

Takeda's vaccine candidate:

A live attenuated tetravalent dengue vaccine is being developed.

Development Phase: Phase 3

Takeda's vaccine candidate:

A virus-like particle vaccine for two norovirus genotypes is being developed.

Development Phase: Phase 2b

Takeda's vaccine candidate:

An inactivated, adjuvanted, whole Zika virus vaccine is being developed with support from the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA).

Development Phase: Phase 1

View Clinical Trials

Takeda's vaccine candidate:

A live attenuated tetravalent dengue vaccine is being developed.

Development Phase: Phase 3

Takeda's vaccine candidate:

A virus-like particle vaccine for two norovirus genotypes is being developed.

Development Phase: Phase 2b

Takeda's vaccine candidate:

An inactivated, adjuvanted, whole Zika virus vaccine is being developed with support from the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA).

Development Phase: Phase 1

NEWSROOM

NEWSROOM:
WE'RE MAKING PROGRESS

Takeda is taking steps towards making an impact on public
health by developing innovative new vaccines. Takeda is taking steps towards making an
impact on public health by developing
innovative new vaccines.

Visit the Takeda Vaccines Newsroom for news releases, videos and infographics.

Swipe to see the five most recent press releases from the Takeda Vaccine Business.

Click the arrows to see the five most recent press releases from the Takeda Vaccine Business.

March 25, 2021

Takeda Begins Regulatory Submissions for Dengue Vaccine Candidate in EU and Dengue-Endemic Countries

Read the full story

March 15, 2021

Takeda and IDT Support Manufacturing of Johnson & Johnson’s COVID-19 Vaccine

Read the full story

February 24, 2021

Takeda Provides Updates on Phase 1/2 Clinical Trials of Novavax’ and Moderna’s COVID-19 Vaccine Candidates in Japan

Read the full story

October 29, 2020

Takeda Expands COVID-19 Vaccine Supply in Japan Through Partnership with Moderna and Government of Japan

Read the full story

August 07, 2020

Novavax and Takeda Announce Collaboration for Novavax’ COVID-19 Vaccine Candidate in Japan

Read the full story

leading the way

Meet the people who are committed to making change. Meet the people who are committed
to making change.

Our team is working passionately toward improving public health.

Click to meet our leaders Swipe to meet our leaders

Explore Takeda Careers

President, Takeda Vaccine Business

Rajeev is President of the Takeda Vaccine Business. He joined Takeda in 2012 to launch the global vaccine business. He was previously Director of Vaccine Delivery in the Global Health Program at the Bill & Melinda Gates Foundation, and prior to that, Special Assistant to the President for Biodefense at the White House.

Head of Development

John is Head of Development for the Takeda Vaccine Business. His prior experience includes Director of the Vaccine Development Global Program at PATH, Executive Director at Merck Research Laboratories and the Deputy Director at the Walter Reed Army Institute of Research in Washington, DC.

Head of Global Medical Office

Gary is Head of the Global Medical Office, and leads the Takeda Vaccine Business Medical Affairs and Policy team. He is responsible for vaccines safety and medical governance. Before joining Takeda, Gary spent the previous 20 years at GSK Vaccines.

Head of Global CMC

Joe is Head of Global CMC for the Takeda Vaccine Business. He is a biotech entrepreneur who previously started two vaccine development companies, Microscience and SingVax (later merged with Inviragen and acquired by Takeda Vaccines in May 2013). Joe has more than 35 years of research and technology experience in cell biology, infectious diseases and industrial microbiology.

Head of Commercial

Rogerio is Head of Commercial for the Takeda Vaccine Business. Before joining Takeda, Rogerio spent more than 20 years at GSK, holding various leadership positions including Senior Vice President and Head of Global Health Unit, Head of Emerging Markets Region, and Senior Vice President & Area Head, Latin America.

Head of Commercial Manufacturing & Supply

Tom is the Head of Commercial Manufacturing & Supply for the Takeda Vaccine Business, and joined Takeda in 2016. His prior experience in vaccines includes strategy and operations roles at Novartis and Seqirus. He previously worked at McKinsey & Co. in the US and Japan, and in engineering roles at Merck.

Head of Finance

Tetsu has been Head of Finance for the Takeda Vaccine Business since 2013. Prior to that Tetsu was at Millennium Pharmaceuticals since 2001, and he joined Takeda through the acquisition of Millennium in 2008.

Head of Vaccine Quality

Paula is the Head of Quality for the Takeda Vaccine Business. She has 35 years of pharmaceutical experience in various functional roles, including manufacturing, quality control microbiology and local/global quality assurance roles at Pfizer, Wyeth and Alcon. Her experience includes international on-site assignments and responsibility for global sites and service providers.

Head of Vaccine Communications

Amy is Head of Communications for the Takeda Vaccine Business, prior to which she was Director of Public Relations for Takeda’s Global Oncology Business Unit. Amy has more than 20 years of experience in all facets of corporate communications, including communication leadership roles at Genzyme, Sanofi Oncology and National Grid.

Head of Human Resources

Kay is the Head of Human Resources for the Takeda Vaccine Business. He joined Takeda in 2006 and worked in Takeda’s R&D organization before joining the Vaccine business. Kay has more than 20 years of HR experience, and worked at NEC Corporation prior to Takeda.

Head Counsel

Rupa is Head Counsel for the Takeda Vaccine Business. She has been practicing law for over 20 years. Prior to joining Takeda, Rupa held legal positions with increasing responsibilities at various biotech companies including Stealth BioTherapeutics, Sage Therapeutics, Biogen and Boston Scientific Corporation.

Explore Takeda Careers

Our team is working passionately toward improving public health.

Swipe to meet our leaders

President, Takeda Vaccine Business

Rajeev is President of the Takeda Vaccine Business. He joined Takeda in 2012 to launch the global vaccine business. He was previously Director of Vaccine Delivery in the Global Health Program at the Bill & Melinda Gates Foundation, and prior to that, Special Assistant to the President for Biodefense at the White House.

Head of Development

John is Head of Development for the Takeda Vaccine Business. His prior experience includes Director of the Vaccine Development Global Program at PATH, Executive Director at Merck Research Laboratories and the Deputy Director at the Walter Reed Army Institute of Research in Washington, DC.

Head of Global Medical Office

Gary is Head of the Global Medical Office, and leads the Takeda Vaccine Business Medical Affairs and Policy team. He is responsible for vaccines safety and medical governance. Before joining Takeda, Gary spent the previous 20 years at GSK Vaccines.

Head of Global CMC

Joe is Head of Global CMC for the Takeda Vaccine Business. He is a biotech entrepreneur who previously started two vaccine development companies, Microscience and SingVax (later merged with Inviragen and acquired by Takeda Vaccines in May 2013). Joe has more than 35 years of research and technology experience in cell biology, infectious diseases and industrial microbiology.

Head of Commercial

Rogerio is Head of Commercial for the Takeda Vaccine Business. Before joining Takeda, Rogerio spent more than 20 years at GSK, holding various leadership positions including Senior Vice President and Head of Global Health Unit, Head of Emerging Markets Region, and Senior Vice President & Area Head, Latin America.

Head of Commercial Manufacturing & Supply

Tom is the Head of Commercial Manufacturing & Supply for the Takeda Vaccine Business, and joined Takeda in 2016. His prior experience in vaccines includes strategy and operations roles at Novartis and Seqirus. He previously worked at McKinsey & Co. in the US and Japan, and in engineering roles at Merck.

Head of Finance

Tetsu has been Head of Finance for the Takeda Vaccine Business since 2013. Prior to that Tetsu was at Millennium Pharmaceuticals since 2001, and he joined Takeda through the acquisition of Millennium in 2008.

Head of Vaccine Quality

Paula is the Head of Quality for the Takeda Vaccine Business. She has 35 years of pharmaceutical experience in various functional roles, including manufacturing, quality control microbiology and local/global quality assurance roles at Pfizer, Wyeth and Alcon. Her experience includes international on-site assignments and responsibility for global sites and service providers.

Head of Vaccine Communications

Amy is Head of Communications for the Takeda Vaccine Business, prior to which she was Director of Public Relations for Takeda’s Global Oncology Business Unit. Amy has more than 20 years of experience in all facets of corporate communications, including communication leadership roles at Genzyme, Sanofi Oncology and National Grid.

Head of Human Resources

Kay is the Head of Human Resources for the Takeda Vaccine Business. He joined Takeda in 2006 and worked in Takeda’s R&D organization before joining the Vaccine business. Kay has more than 20 years of HR experience, and worked at NEC Corporation prior to Takeda.

Head Counsel

Rupa is Head Counsel for the Takeda Vaccine Business. She has been practicing law for over 20 years. Prior to joining Takeda, Rupa held legal positions with increasing responsibilities at various biotech companies including Stealth BioTherapeutics, Sage Therapeutics, Biogen and Boston Scientific Corporation.

1World

It's the single thing that

that connects us all

­estimated $60.3 BILLION

­estimated $60.3 BILLION ANNUAL ECONOMIC IMPACT WORLDWIDE[2]